BHWM
KYMR icon

Bay Harbor Wealth Management’s Kymera Therapeutics KYMR Stock Holding History

Bay Harbor Wealth Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115 Hold
1
– – ﹤0.01% 1222
2026
Q1 		$83 Hold
1
– – ﹤0.01% 1226
2025
Q4 		$77 Buy
+1
New +$68 ﹤0.01% 1228

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bay Harbor Wealth Management's KYMR Position: Q2 2026 in Review

Bay Harbor Wealth Management held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 1 share worth $115. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

Bay Harbor Wealth Management first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Bay Harbor Wealth Management held 1 share of Kymera Therapeutics worth $115 as of Q2 2026.
  • Bay Harbor Wealth Management left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #1222 holding.
  • Bay Harbor Wealth Management first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.